API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
EU WC
0
Listed Suppliers
0
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
https://www.prnewswire.com/news-releases/yingli-pharma-presents-a-pivotal-phase-2-study-data-evaluating-linperlisib-in-relapsed-or-refractory-peripheral-t-cell-lymphoma-in-an-oral-session-at-the-american-society-of-hematology-2023-annual-meeting-302010879.html
https://www.prnewswire.com/news-releases/yingli-pharma-announces-a-presentation-on-the-phase-2-clinical-trial-of-linperlisib-a-pi3k-selective-inhibitor-in-relapsed-or-refractory-follicular-lymphoma-at-the-european-hematology-association-2021-congress-301310715.html
https://www.prnewswire.com/news-releases/yingli-pharma-announces-a-presentation-on-the-phase-2-clinical-trial-of-linperlisib-a-pi3k-selective-inhibitor-in-relapsed-or-refractory-follicular-lymphoma-at-the-european-hematology-association-2021-congress-301310715.html
https://www.prnewswire.com/news-releases/yingli-pharma-announces-a-presentation-on-the-phase-2-clinical-trial-of-linperlisib-a-pi3k-selective-inhibitor-in-relapsed-or-refractory-follicular-lymphoma-at-the-european-hematology-association-2021-congress-301310715.html
https://www.prnewswire.com/news-releases/yingli-pharma-announces-a-presentation-on-the-phase-2-clinical-trial-of-linperlisib-a-pi3k-selective-inhibitor-in-relapsed-or-refractory-follicular-lymphoma-at-the-european-hematology-association-2021-congress-301310715.html